论文部分内容阅读
目的观察舒利迭(沙美特罗替卡松干粉吸入剂)治疗中度支气管哮喘的效果。方法把确诊为中度支气管哮喘的64例患者随机分为治疗组(32例)和对照组(32例),治疗组每日吸舒利迭2次,共24周;对照组每日吸辅舒酮2次,共24周。治疗期间两组按需使用喘乐宁气雾剂以控制症状。分别于治疗前、治疗后第1、4、8、12、24周测量肺功能(PEF、FEV1)。治疗前后测定外周血淋巴细胞亚群(CD4、CD8、CD4/CD8)。结果治疗组在治疗后第1周症状和肺功能(PEF、FEV1)即明显改善(P<0.05),CD8增加,与治疗前比较(P<0.01)。结论舒利迭治疗中度哮喘有较显著的临床效果,在控制哮喘症状、改善肺功能和增强患者免疫力方面,舒利迭较辅舒酮效果更好。
Objective To observe the effect of seretide (salmeterol ticlatrex dry powder inhalation) in the treatment of moderate bronchial asthma. Methods Sixty-four patients diagnosed with moderate bronchial asthma were randomly divided into treatment group (32 cases) and control group (32 cases). The treatment group was given sullypirin twice daily for 24 weeks. In the control group, Shu ketone 2 times, a total of 24 weeks. During the treatment, two groups were used asthma oral aerosol to control the symptoms. Pulmonary function (PEF, FEV1) was measured before treatment and at 1, 4, 8, 12 and 24 weeks after treatment. Peripheral blood lymphocyte subsets (CD4, CD8, CD4 / CD8) were measured before and after treatment. Results The symptoms and pulmonary function (PEF, FEV1) of the treatment group were significantly improved (P <0.05) and CD8 increased in the first week after treatment, compared with those before treatment (P <0.01). Conclusion Seretide treatment of moderate asthma has a more significant clinical effect, in the control of asthma symptoms, improve lung function and enhance patient immunity, Seretide better than doxerone.